Overall, this study provides evidence that increased levels of the lncRNA CASC10 contribute to the cisplatin resistance of ovarian cancer cells and that a liposomal formulation of siRNA-CASC10 is a reasonable strategy for ovarian cancer treatment. The gene discussed is MIR1915HG; the disease is ovarian carcinoma.